transmission level in progress.
“We have experienced Delta shock, and now the Omicron shock … there is a potential scenario where our vaccines may become ineffective in new situations in the wake of the last three weeks we have been living with Omicron, we have seen “How such doubts have arisen, some of them may be genuine, we still do not have the final picture,” he said. with the changing nature of the varieties.
“How fast can we create a vaccine that uses the same platform, but which is now targeted at today’s variant … we may need to think about how we do it.” … in relation to the rapid development of generic vaccine , we must be ready to be able to have a situation where we are resiliently able to modify the vaccines as needed (d). This may not happen every three months, but it may happen every year. That is why it must be taken into account, ”said Paul.
The new COVID variant called B.1.1.529 or Omicron was first reported to the World Health Organization (WHO) from South Africa on 24 November. According to Paul, drug development will not go out of fashion for the next viral epidemic / pandemic the world may face, and this challenge of antimicrobial resistance is also calling for drug solutions.
Noting that there is a need to examine how India’s classic pharmaceutical industry can have a roadmap and a risk-taking stance, he said: “We are still crying out for an effective drug to fight viral diseases, including COVID”. The coronavirus pandemic has learned that viruses cannot be taken lightly and the unpredictability of new health scenarios must be respected and addressed, Paul noted.
“The pandemic is not over, we will continue to deal with uncertainty, although we hope that we may move towards endemicity, hopefully of a mild disease that we can tackle,” Paul said, but warned that the situation did not can be taken for granted. The endemic phase is when a population learns to live with a virus. It is very different from the epidemic where the virus overwhelms a population.
Noting that the industry’s contribution to science is low in the country, Paul said, “Our national investment in science is all public money … even during the development of the vaccines, a lot of testing was done in the national laboratory”. He further said that 97 per cent of the vaccines delivered to Indian people were with public money and very little with private money.
The top priority right now is to ensure that there is universal coverage of the vaccine and that no one is left behind, Paul said, adding that globally, there are 3.6 billion people who have not been vaccinated. “We need 7.2 billion doses together, and with the current production rate, it’s well within our reach … it’s possible for us to deliver the vaccine,” Paul said.